Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Introduction: MRD positivity after induction/consolidation therapy in pts with de novo ALL has been shown to carry a very negative impact on outcome. However, the significance of MRD status in the salvage setting has not been extensively studied.
Methods: We evaluated 130 pts with R/R B-cell ALL pts who received first (n=68), or second (n=62), salvage therapy between 2010 and 2015. Salvage therapies included single agent inotuzumab ozogamicin (INO; n=75), blinatumomab (n=20), or INO in combination with mini-hyper-CVD (n=35) [Jabbour E et al; EHA 2015]. Of the 130 pts treated, 78 (60%) responded and were assessed for MRD by six-color flow cytometry on marrow samples with a sensitivity of 0.01%. Morphologic responses were defined as follows, complete response (CR); disappearance of all disease with neutrophils ≥ 1.0 X 109/L, platelet > 100 X 109/L and blasts ≤ 5%, CRp; CR without platelet recovery, CRi; CR without platelet and/or neutrophil recovery.
Results: The clinical characteristics of the 78 responding pts with R/R ALL are summarized in Table 1. Overall, MRD negativity was achieved at response in 41 pts (53%). Among the 41 pts who responded to single agent INO (12 CR, 26 CRp, 3CRi), 17 (41%) achieved a negative MRD status. Among the 11 pts who responded to blinatumomab (9 CR, 2Cri), 8 (73%) achieved a negative MRD status. Among the 26 pts who responded to INO in combination with mini-HCVD (21 CR, 4 CRp, 1CRi), 16 (62%) achieved a negative MRD status. Forty-four pts received allogeneic stem cell transplantation (ASCT): of those, 21 pts were MRD negative and 23 pts were MRD positive at the time of response. Median follow-up was 19 months (2-55). Overall, there was a trend for more durable morphologic responses in MRD negative pts compared with MRD positive pts: the median complete remission durations (CRD) were 17 months and 8 months, with a 2-year CRD rate of 47% and 28% respectively (Table 2). The median event-free survival (EFS) was 12 and 6 months, respectively; the 2-year EFS rates were 32% and 8%, respectively. Similarly, there was a trend for better overall survival (OS) with a median of 17 months and 9 months for pts with negative and positive MRD, respectively; the 2-year OS rates were 36% and 27%, respectively. No difference in outcome was reported whether pts were censored or not at the time of ASCT.
Conclusion: In pts with R/R ALL, the achievement of negative MRD in addition to the morphologic response confers an improvement, although not statistically significant, in response duration and survival. Larger number of pts with longer follow-up is needed to validate these findings.
Table 1. Clinical Characteristics of Pts (n=78) | |
| N (%)/Median [range] |
Age (years) | 38 [18-87] |
Sex (Male) | 50 (64) |
Performance Status | 1 [1-3] |
WBC (x 109/L) | 3 [0.3-38] |
% PB Blasts | 0 [0-83] |
% BM Blasts | 60 [8-97] |
Cytogenetics | |
Diploid | 20 (26) |
t(9;22) | 4 (5) |
t(4;11) | 7 (9) |
Miscellaneous | 39 (50) |
Not done/ Insufficient metaphases | 8 (10) |
Salvage |
|
Inotuzumab Ozogamicin | 41 (53) |
Blinatumomab | 11 (14) |
Inotuzumab Ozogamicin + mini-HCVD | 26 (33) |
Number of prior therapies |
|
1 prior therapy | 46 (59) |
2 prior therapies | 32 (41) |
Table 2. Response Rates and Survival by MRD Status | |||
| MRD Negative (n=41) | MRD Positive (n=37) | p |
CR | 24 | 18 | n/a |
CRp | 16 | 14 | n/a |
CRi | 1 | 5 | n/a |
CRD, median (m) | 17 | 8 | 0.63 |
2-year CRD rate (%) | 47 | 28 | |
EFS, median (m) | 12 | 6 | 0.06 |
2-year EFS rate (%) | 32 | 8 | |
OS, median (m) | 17 | 9 | 0.18 |
2-year OS rate (%) | 36 | 27 |
Disclosures: Cortes: Teva: Research Funding ; BMS: Consultancy , Research Funding ; Novartis: Consultancy , Research Funding ; BerGenBio AS: Research Funding ; Pfizer: Consultancy , Research Funding ; Ariad: Consultancy , Research Funding ; Astellas: Consultancy , Research Funding ; Ambit: Consultancy , Research Funding ; Arog: Research Funding ; Celator: Research Funding ; Jenssen: Consultancy . DiNardo: Novartis: Research Funding .
See more of: Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
See more of: Oral and Poster Abstracts
*signifies non-member of ASH